A review of anemia as a cardiovascular risk factor in patients with myelodysplastic syndromes

por Oliva, Esther N, Schey, Carina, Hutchings, Adam S
Publicado 2011

Costs and quality of life in patients with myelodysplastic syndromes

por Lucioni, Carlo, Finelli, Carlo, Mazzi, Silvio, Oliva, Esther N
Publicado 2013

Prospective changes of cardiac iron and function in low and intermediate-1 risk mds patients

por Pepe, Alessia, Meloni, Antonella, Carulli, Giovanni, Oliva, Esther N, Arcioni, Francesco, Storti, Sergio, Neri, Mari Giovanna, Grassedonio, Emanuele, Renne, Stefania, Restaino, Gennaro, Positano, Vincenzo, Rizzo, Michele
Publicado en J Cardiovasc Magn Reson (2015)

Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians

por Oliva, Esther N., Nobile, Francesco, Alimena, Giuliana, Ronco, Francesca, Specchia, Giorgina, Impera, Stefana, Breccia, Massimo, Vincelli, Iolanda, Carmosino, Ida, Guglielmo, Patrizia, Pastore, Domenico, Alati, Caterina, Latagliata, Roberto
Publicado 2011

Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome

por Caracciolo, Massimo, Macheda, Sebastiano, Labate, Demetrio, Tescione, Marco, La Scala, Stefano, Vadalà, Eugenio, Squillaci, Rosalba, D’Aleo, Francesco, Morabito, Antonella, Garreffa, Cristina, Marciano, Maria Concetta, Oliva, Esther N.
Publicado en Front Immunol (2020)

A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes

por Fang, Jing, Liu, Xiaona, Bolanos, Lyndsey, Barker, Brenden, Rigolino, Carmela, Cortelezzi, Agostino, Oliva, Esther N, Cuzzola, Maria, Grimes, H Leighton, Fontanillo, Celia, Komurov, Kakajan, MacBeth, Kyle, Starczynowski, Daniel T
Publicado en Nat Med (2016)

Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1

por Fang, Jing, Rhyasen, Garrett, Bolanos, Lyndsey, Rasch, Christopher, Varney, Melinda, Wunderlich, Mark, Goyama, Susumu, Jansen, Gerrit, Cloos, Jacqueline, Rigolino, Carmela, Cortelezzi, Agostino, Mulloy, James C., Oliva, Esther N., Cuzzola, Maria, Starczynowski, Daniel T.
Publicado 2012

Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content Validity

por Goswami, Pushpendra, Oliva, Esther N., Ionova, Tatyana, Else, Roger, Kell, Jonathan, Fielding, Adele K., Jennings, Daniel M., Karakantza, Marina, Al-Ismail, Saad, Collins, Graham P., McConnell, Stewart, Langton, Catherine, Salek, Sam
Publicado en Front Pharmacol (2020)

Quality-of-life issues and symptoms reported by patients living with haematological malignancy: a qualitative study

por Goswami, Pushpendra, Oliva, Esther N., Ionova, Tatyana, Else, Roger, Kell, Jonathan, Fielding, Adele K., Jennings, Daniel M., Karakantza, Marina, Al-Ismail, Saad, Collins, Graham P., McConnell, Stewart, Langton, Catherine, Salek, Sam
Publicado en Ther Adv Hematol (2020)

Outcome of therapy-related myeloid neoplasms treated with azacitidine

por Fianchi Luana, Criscuolo Marianna, Lunghi Monia, Gaidano Gianluca, Breccia Massimo, Levis Alessandro, Finelli Carlo, Santini Valeria, Musto Pellegrino, Oliva Esther N, Leoni Pietro, Spiriti Antonietta, D’Alò Francesco, Hohaus Stefan, Pagano Livio, Leone Giuseppe, Voso Maria
Publicado 2012-08-01

Outcome of therapy-related myeloid neoplasms treated with azacitidine

por Fianchi, Luana, Criscuolo, Marianna, Lunghi, Monia, Gaidano, Gianluca, Breccia, Massimo, Levis, Alessandro, Finelli, Carlo, Santini, Valeria, Musto, Pellegrino, Oliva, Esther N, Leoni, Pietro, Aloe Spiriti, Antonietta, D’Alò, Francesco, Hohaus, Stefan, Pagano, Livio, Leone, Giuseppe, Voso, Maria Teresa
Publicado 2012

Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study

por Goswami, Pushpendra, Oliva, Esther N., Ionova, Tatyana, Else, Roger, Kell, Jonathan, Fielding, Adele K., Jennings, Daniel M., Karakantza, Marina, Al-Ismail, Saad, Collins, Graham P., McConnell, Stewart, Langton, Catherine, Al-Obaidi, Magda J., Oblak, Metod, Salek, Sam
Publicado en Front Pharmacol (2020)

Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO

por Goswami, Pushpendra, Oliva, Esther N., Ionova, Tatyana, Else, Roger, Kell, Jonathan, Fielding, Adele K., Jennings, Daniel M., Karakantza, Marina, Al-Ismail, Saad, Collins, Graham P., McConnell, Stewart, Langton, Catherine, Al-Obaidi, Magda J., Oblak, Metod, Salek, Sam
Publicado en Front Pharmacol (2020)

Early lenalidomide treatment for low and intermediate‐1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence

por Oliva, Esther N., Lauseker, Michael, Aloe Spiriti, Maria Antonietta, Poloni, Antonella, Cortelezzi, Agostino, Palumbo, Giuseppe A., Balleari, Enrico, Sanpaolo, Grazia, Volpe, Antonio, Ricco, Alessandra, Ronco, Francesca, Alati, Caterina, D'Errigo, Maria Grazia, Santacaterina, Irene, Kündgen, Andrea, Germing, Ulrich, Latagliata, Roberto
Publicado en Cancer Med (2015)

Targeting IRAK1 as a therapeutic approach for Myelodysplastic Syndrome

por Rhyasen, Garrett W., Bolanos, Lyndsey, Fang, Jing, Jerez, Andres, Wunderlich, Mark, Rigolino, Carmela, Mathews, Lesley, Ferrer, Marc, Southall, Noel, Guha, Rajarshi, Keller, Jonathan, Thomas, Craig, Beverly, Levi J., Cortelezzi, Agostino, Oliva, Esther N., Cuzzola, Maria, Maciejewski, Jaroslaw P., Mulloy, James C., Starczynowski, Daniel T.
Publicado 2013